Dedicated to the Discovery of Regenerative Medicines.
ChemRegen is one of the first regenerative medicine research and development companies that combines state of the art stem cell biology and drug development. Located in San Diego, California, ChemRegen is one of the first regenerative medicine research and development companies that combines state of the art stem cell biology and drug development.
Our initial technology is based on work done in collaboration between Dr. Mark Mercola of the Sanford Burnham Research Institute (a recognized authority on stem cell biology, and who serves as President for ChemRegen), and Dr. John Cashman of the Human BioMolecular Research Institute (a recognized authority on drug development and who also serves as Chief Operating Officer of ChemRegen).
With a global, cutting edge scientific team, ChemRegen delivers reliable, regenerative medicine development expertise to the emerging area of regenerative medicine drug discovery. ChemRegen provides quality, precision research with state of the art methods, delivering design, implementation, and interpretation of pre-clinical regenerative medicine drug development with timely, cost-efficient, and reliable methods.
ChemRegen’s mission is to develop “first in class” treatments using cutting edge chemical and biological science in stem cell biology.